Key Takeaways BDX delivered an adjusted EPS beat and reported quarterly revenues of $5.25 billion, exceeding expectations.BDX expanded gross margin to 45.9% and lifted adjusted operating margin to 13.6% on higher operating profit.BDX saw revenue growth across most segments, partly offset by a decline in the Life Sciences business.Becton, Dickinson and Company (BDX) , popularly known as BD, delivered adjusted earnings per share (EPS) of $2.91 in the first quarter of fiscal 2026, down 15.2% year over year. Th ...

FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered strongerthanexpected firstquarter performance which reflects our disciplined execution, including accelerated commercial initiatives and broadbased growth across key end markets," said Tom Polen, chairman, CEO and president of BD. "Today, we expect to complete the ...

Core Insights - Becton, Dickinson and Company (BDX) has announced a collaboration with ChemoGLO to enhance hazardous drug contamination testing in healthcare settings, aiming to improve safety for healthcare workers [1][8] Company Developments - The collaboration is a strategic move to strengthen BDX's Medication Delivery Solutions (MDS) business unit within the BD Medical segment [2] - The partnership will integrate BD HD Check System's rapid qualitative results with ChemoGLO's advanced analytical methods, providing comprehensive quantitative reports on hazardous drugs within three to five days [4][5] - BDX's management anticipates that this collaboration will enable quicker identification of contamination risks and enhance understanding of exposure risks [5] Market Performance - Following the announcement, BDX shares increased by nearly 0.1%, with a current market capitalization of $55.54 billion and an earnings yield of 7.7%, surpassing the industry average of 5.8% [3] - Over the past year, BDX shares have decreased by 11.1%, contrasting with an 8% rise in the industry and a 15.3% gain in the S&P 500 [9] Industry Outlook - The global drug screening market is projected to grow from $15.4 billion in 2025 to $52.2 billion in 2034, at a compound annual growth rate (CAGR) of 14.5%, driven by increasing concerns over substance abuse and stricter regulatory requirements [6]